Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence

C. Belluco; G. Esposito; R. Bertorelle; R. Alaggio; L. Giacomelli; L. C. Bianchi; D. Nitti; M. Lise

doi:10.1053/ejso.2001.1223

Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence

C. Belluco, G. Esposito, R. Bertorelle, R. Alaggio, L. Giacomelli, L. C. Bianchi, D. Nitti, M. Lise

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (r_s=0.677; P

Original language	English
Pages (from-to)	120-125
Number of pages	6
Journal	European Journal of Surgical Oncology
Volume	28
Issue number	2
DOIs	https://doi.org/10.1053/ejso.2001.1223
Publication status	Published - Mar 2002

Keywords

Adenoma-carcinoma sequence
Colorectal cancer
Fas ligand

ASJC Scopus subject areas

Oncology
Surgery

Access to Document

10.1053/ejso.2001.1223

Cite this

@article{a1bba8e7269f41df9a13c8c6e547272c,

title = "Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence",

abstract = "Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (rs=0.677; P",

keywords = "Adenoma-carcinoma sequence, Colorectal cancer, Fas ligand",

author = "C. Belluco and G. Esposito and R. Bertorelle and R. Alaggio and L. Giacomelli and Bianchi, {L. C.} and D. Nitti and M. Lise",

year = "2002",

month = mar,

doi = "10.1053/ejso.2001.1223",

language = "English",

volume = "28",

pages = "120--125",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence

AU - Belluco, C.

AU - Esposito, G.

AU - Bertorelle, R.

AU - Alaggio, R.

AU - Giacomelli, L.

AU - Bianchi, L. C.

AU - Nitti, D.

AU - Lise, M.

PY - 2002/3

Y1 - 2002/3

N2 - Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (rs=0.677; P

AB - Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (rs=0.677; P

KW - Adenoma-carcinoma sequence

KW - Colorectal cancer

KW - Fas ligand

UR - http://www.scopus.com/inward/record.url?scp=0036489996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036489996&partnerID=8YFLogxK

U2 - 10.1053/ejso.2001.1223

DO - 10.1053/ejso.2001.1223

M3 - Article

C2 - 11884046

AN - SCOPUS:0036489996

VL - 28

SP - 120

EP - 125

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 2

ER -

Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this